ReviewClinical and experimental medicine2026

CK2 in triple-negative breast cancer: oncogenic signaling networks and emerging CK2 inhibitor-based combination therapies.

Navas Shereef Ellyan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.